JP2020515649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515649A5 JP2020515649A5 JP2020503374A JP2020503374A JP2020515649A5 JP 2020515649 A5 JP2020515649 A5 JP 2020515649A5 JP 2020503374 A JP2020503374 A JP 2020503374A JP 2020503374 A JP2020503374 A JP 2020503374A JP 2020515649 A5 JP2020515649 A5 JP 2020515649A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- agent
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 229940127089 cytotoxic agent Drugs 0.000 claims 10
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical group C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- -1 taxans Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024207994A JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704910.7A GB201704910D0 (en) | 2017-03-28 | 2017-03-28 | High dose combi I |
| GB1704910.7 | 2017-03-28 | ||
| GB1718806.1 | 2017-11-14 | ||
| GBGB1718806.1A GB201718806D0 (en) | 2017-11-14 | 2017-11-14 | Breast cancer treatment |
| PCT/GB2018/050843 WO2018178690A1 (en) | 2017-03-28 | 2018-03-28 | An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207994A Division JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515649A JP2020515649A (ja) | 2020-05-28 |
| JP2020515649A5 true JP2020515649A5 (enExample) | 2021-04-30 |
| JP7657590B2 JP7657590B2 (ja) | 2025-04-07 |
Family
ID=61952738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503374A Active JP7657590B2 (ja) | 2017-03-28 | 2018-03-28 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
| JP2024207994A Pending JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207994A Pending JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200101066A1 (enExample) |
| EP (1) | EP3600433B1 (enExample) |
| JP (2) | JP7657590B2 (enExample) |
| KR (2) | KR20200072445A (enExample) |
| CN (1) | CN111050801B (enExample) |
| AU (1) | AU2018244806B2 (enExample) |
| CA (1) | CA3083850A1 (enExample) |
| ES (1) | ES2897790T3 (enExample) |
| WO (1) | WO2018178690A1 (enExample) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE326222T1 (de) | 2000-03-15 | 2006-06-15 | Wolfgang Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| EP1479381A1 (en) * | 2003-05-19 | 2004-11-24 | Euro-Celtique S.A. | Pharmaceutical dosage form comprising a solid solution |
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| AU2006275914A1 (en) * | 2005-07-27 | 2007-02-08 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| JP6008866B2 (ja) * | 2010-12-03 | 2016-10-19 | オレキシジェン・セラピューティクス・インコーポレーテッド | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
| JP2015107918A (ja) | 2012-02-14 | 2015-06-11 | 国立研究開発法人国立がん研究センター | 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法 |
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| WO2016061531A1 (en) * | 2014-10-17 | 2016-04-21 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
| GB201704911D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
-
2018
- 2018-03-28 KR KR1020197031888A patent/KR20200072445A/ko not_active Ceased
- 2018-03-28 AU AU2018244806A patent/AU2018244806B2/en active Active
- 2018-03-28 WO PCT/GB2018/050843 patent/WO2018178690A1/en not_active Ceased
- 2018-03-28 US US16/499,230 patent/US20200101066A1/en active Pending
- 2018-03-28 CA CA3083850A patent/CA3083850A1/en active Pending
- 2018-03-28 ES ES18717108T patent/ES2897790T3/es active Active
- 2018-03-28 EP EP18717108.7A patent/EP3600433B1/en active Active
- 2018-03-28 CN CN201880035530.6A patent/CN111050801B/zh active Active
- 2018-03-28 JP JP2020503374A patent/JP7657590B2/ja active Active
- 2018-03-28 KR KR1020247026962A patent/KR20240125082A/ko active Pending
-
2024
- 2024-11-29 JP JP2024207994A patent/JP2025027084A/ja active Pending